



BOZ TIBBI

MALZEME SANAYİ VE TİCARET A.Ş.

# **Declaration of Conformity**

Manufacturer

BOZ TIBBİ MALZEME SANAYİ VE TİCARET A.Ş.

Address

Sağlık Mah. Sağlık 1 Sk. No:33/5 Çankaya / ANKARA / TÜRKİYE

Product Name

**REOXCEL Sigma Knit** 

Absorbable Haemostat Oxidized Regenerated Cellulose (ORC)

**Properties** 

Sterile, Single Use

Dye

Undyed (natural, beige-caramel)

Insulation/Coating

Sizes

For product models, see page 2

**GMDN NO** 

38771

Classification

Class III, Rule 7

We herewith declare that the above mentioned products meet the provisions of the following EC Council Directives and Standards. All supporting documentations are retained under the premises of the manufacturer and the notified body. It conforms to Conformity Assessment Route Annex 2, article for 4 of the 93/42/EEC directive.

### **DIRECTIVES**

General applicable directives:

-Medical Device Directive: COUNCIL DIRECTIVE 93/42/EEC of 14 June 1993 Included Amendment 2007/47/EC concerning medical devices (MDD 93/42/EEC).

#### Standards:

For Applicable Standards List, see page 3, 4, 5 and 6

**Notified Body** 

: UDEM Uluslararası Belgelendirme Denetim Egitim Merkezi San. ve Tic. A.S.

Mutlukent Mahallesi 2073 Sokak No:10 Ümitköy-ÇANKAYA Ankara Türkiye

**Notified Body No** 

| Certificate                          | Certificate No    | Certificate Date | Date of Validity |
|--------------------------------------|-------------------|------------------|------------------|
| EC Design-Examination<br>Certificate | M.2018.106.9142-1 | 02.01.2018       | 01.01.2023       |
| Full Quality Assuarance<br>System    | M.2018.106,9142   | 02.01.2018       | 01.01.2023       |

Place, Date

Ankara, 02.10.2023

Signature

Digitally signed by Rotari Vladimir Date: 2023.12.08 17:49:48 EET Reason: MoldSign Signature

Location: Moldova

Name Position

Adu BOZ General Manager

Document Code: Effective Date: Revision No: Revision Date: Number of Pages: YT-DC-RK 11.09.2012 02.10.2023 1/6



# BOZ

## BOZ TIBBİ MALZEME SANAYÎ VE TİCARET A.Ş.

### REOXCEL Sigma Knit (Oxidized Regenerated Cellulose Haemostat) PRODUCT MODELS

| PRODUCT CODE | PRODUCT SIZE          | PRODUCT CODE | PRODUCT SIZE   |
|--------------|-----------------------|--------------|----------------|
| RK1001*      | RK1001* 2,6cm x 2,6cm |              | 2,6cm x 2,6cm  |
| RK1001X*     | 2,6cm x 2,6cm         | RK1001X      | 2,6cm x 2,6cm  |
| RK1003*      | 2,6cm x 10cm          | RK1003       | 2,6cm x 10cm   |
| RK1003X*     | 2,6cm x 10cm          | RK1003X      | 2,6cm x 10cm   |
| RK2003*      | 5cm x 7,5cm           | RK2003       | 5cm x 7,5cm    |
| RK2003X*     | 5cm x 7,5cm           | RK2003X      | 5cm x 7,5cm    |
| RK3004*      | 7,6cm x 10,2cm        | RK3004       | 7,6cm x 10,2cm |
| RK3004X*     | 7,6cm x 10,2cm        | RK3004X      | 7,6cm x 10,2cm |
| RK6009*      | 15,2cm x 23cm         | RK6009       | 15,2cm x 23cm  |

| Document Code : | Effective Date: | Revision No: | Revision Date: | Number of Pages: |
|-----------------|-----------------|--------------|----------------|------------------|
| YT-DC-RK        | 11.09.2012      | 11           | 02.10.2023     | 2/6              |



### DIRECTIVE/REGULATION/STANDARD/COMMON SPECIFICATION/GUIDANCE

| NO | REFERENCE                     | TITLE   |  |  |
|----|-------------------------------|---|--|--|
| 1  | 2017/745                      | Regulation (Eu) 2017/745 of the European Parliament and of the Council of 5 April 2017  |  |  |
| 2  | EN ISO 13485:2016+A11:2021    | Medical devices — Quality management systems —Requirements for regulatory purposes (ISO 13485:2016)   |  |  |
| 3  | EN ISO 14971:2019+A11         | Medical devices – Application of risk management to medical devices (ISO 14971:2019)  |  |  |
| 4  | USP                           | United States Pharmacopeia (USP) 43 National Formulary (NF) 38<br>Oxidized Regenerated Cellulose Monograph  |  |  |
| 5  | EN 556-1:2001/AC:2006         | Sterilization of medical devices - Requirements for medical devices to be designated<br>'STERILE' - Part 1: Requirements for terminally sterilized medical devices  |  |  |
| 6  | EN ISO 10993-1:2020           | Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process (ISO 10993-1:2018, including corrected version 2018-10)  |  |  |
| 7  | EN ISO 10993-3:2014           | Biological evaluation of medical devices Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity (ISO 10993-3:2014)   |  |  |
| 8  | EN ISO 10993-4:2017           | Biological evaluation of medical devices Part 4: Selection of tests for interactions with blood (ISO 10993-4:2017)  |  |  |
| 9  | EN ISO 10993-5:2009           | Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity (ISO 10993-5:2009)   |  |  |
| 10 | EN ISO 10993-6:2016           | Biological evaluation of medical devices Part 6: Tests for local effects after implantation (ISO 10993-6:2016)  |  |  |
| 11 | EN ISO 10993-9:2021           | Biological evaluation of medical devices Part 9: Framework for identification and quantification of potential degradation products (ISO 10993-9:2019)   |  |  |
| 12 | EN ISO 10993-10:2023          | Biological evaluation of medical devices Part 10: Tests for irritation and skin sensitization (ISO 10993-10:2021)   |  |  |
| 13 | EN ISO 10993-11:2018          | Biological evaluation of medical devices Part 11: Tests for systemic toxicity (ISO 10993-11:2017)   |  |  |
| 14 | EN ISO 10993-12:2021          | Biological evaluation of medical devices Part 12: Sample preparation and reference materials (ISO 10993-12:2021)  |  |  |
| 15 | EN ISO 10993-13:2010          | Biological evaluation of medical devices Part 13: Identification and quantification of degradation products from polymeric medical devices (ISO 10993-13:2010)  |  |  |
| 16 | EN ISO 10993-16:2017          | Biological evaluation of medical devices Part 16: Toxicokinetic study design for degradation products and leachables (ISO 10993-16:2017)  |  |  |
| 17 | EN ISO 10993-17:2009          | Biological evaluation of medical devices Part 17: Establishment of allowable limits for leachable substances (ISO 10993-17:2002)  |  |  |
| 18 | EN ISO 10993-18:2020/ A1:2023 | Biological evaluation of medical devices - Part 18: Chemical characterization of medical device materials within a risk management process - Amendment 1: Determination of the uncertainty factor (ISO 10993-18:2020/Amd 1:2022)                |  |  |
| 19 | EN ISO 10993-23:2021          | Biological evaluation of medical devices - Part 23: Tests for irritation (ISO 10993-23:2021)  |  |  |
| 20 | EN ISO 14630:2012             | Non-active surgical implants - General requirements (ISO 14630:2012)  |  |  |
| 21 | EN 62366-1:2015/A1:2020       | Medical devices - Part 1: Application of usability engineering to medical devices   |  |  |
| 22 | EN ISO 11137-1:2015/A2:2019   | Sterilization of health care products - Radiation - Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices - Amendment 2: Revision to 4.3.4 and 11.2 (ISO 11137-1:2006/Amd 2:2018) |  |  |
| 23 | EN ISO 11137-2:2015/A1:2023   | Sterilization of health care products - Radiation - Part 2: Establishing the sterilization dose - Amendment 1 (ISO 11137-2:2013/Amd 1:2022)  KM-AS-ORC-rev00-25.08.2023   |  |  |

KM-AS-ORC-rev00-25.08.2023

| Document Code : | Effective Date: | Revision No: | Revision Date: | Number of Pages: |  |
|-----------------|-----------------|--------------|----------------|------------------|--|
| YT-DC-RK        | 11.09.2012      | 11           | 02.10.2023     | 3/6              |  |



| heroes those | ************************************** | Starilization of health care products. Padiation Part 2: Cuidanas and desirectain   |
|--------------|--|---|
| 24           | EN ISO 11137-3:2017                    | Sterilization of health care products - Radiation - Part 3: Guidance on dosimetric aspects of development, validation and routine control (ISO 11137-3:2017)                                |
| 25           | EN ISO 11737-1:2018/A1:2021            | Sterilization of health care products - Microbiological methods - Part 1: Determination of a population of microorganisms on products (ISO 11737-1:2018/Amd 1:2021)                         |
| 26           | EN ISO 11737-2:2020                    | Sterilization of medical devices- Microbiological methods- Part 2: Tests of sterility performed in the validation of a sterilization process (ISO 11737-2:2019)                             |
| 27           | EN ISO 15223-1:2021                    | Medical devices - Symbols to be used with medical device labels, labelling and information to be supplied - Part 1: General requirements (ISO 15223-1:2021)                                 |
| 28           | EN ISO 20417:2021                      | Medical devices - Information to be supplied by the manufacturer (ISO 20417:2021, Corrected version 2021-12)  |
| 29           | EN ISO 14644-1:2015                    | Cleanrooms and associated controlled environments - Part 1: Classification of air cleanliness by particle concentration (ISO 14644-1:2015)  |
| 30           | EN ISO 14644-2:2015                    | Cleanrooms and associated controlled environments - Part 2: Monitoring to provide evidence of cleanroom performance related to air cleanliness by particle concentration (ISO 14644-2:2015) |
| 31           | EN ISO 14644-3:2019                    | Cleanrooms and associated controlled environments - Part 3: Test methods (ISC 14644-3:2019, Corrected version 2020-06)  |
| 32           | EN ISO 14644-5:2004                    | Cleanrooms and associated controlled environments - Part 5: Operations (ISO 14644-5:2004)   |
| 33           | EN 17141:2020                          | Cleanrooms and associated controlled environments - Biocontamination control  |
| 34           | EN ISO 11607-1:2020/A11:2022           | Packaging for terminally sterilized medical devices - Part 1: Requirements for materials, sterile barrier systems and packaging systems (ISO 11607-1:2019)                                  |
| 35           | EN ISO 11607-2:2020/A11:2022           | Packaging for terminally sterilized medical devices - Part 2: Validation requirements for forming, sealing and assembly processes (ISO 11607-2:2019)  |
| 36           | EN 868-5: 2018                         | Packaging for terminally sterilized medical devices - Part 5: Sealable pouches and reels of porous materials and plastic film construction - Requirements and test methods                  |
| 37           | ISO 8601-1:2019/Amd 1:2022             | Date and time — Representations for information interchange — Part 1: Basic rules — Amendment 1: Technical corrections  |
| 38           | ISO 13781:2017                         | Implants for surgery — Homopolymers, copolymers and blends on poly(lactide) — In vitro degradation testing  |
| 39           | CEN ISO/TR 24971:2020                  | Medical devices - Guidance on the application of ISO 14971 (ISO/TR 24971:2020)  |
| 40           | CPMP/ICH/2736/99-Step 5<br>August 2003 | ICH Topic Q 1 A (R2) Stability Testing of New Drug Substances and Drug Products   |
| 41           | TS 4739/ MAR 1986                      | Methods of Identification of Textile Fibers   |
| 42           | TS 10410/ OCT 1992                     | Methods For Sterility Control (For Medical Purposes)  Part 3- Application Of Medicines, Medical And Surgical Materials To Inoculation Methods   |
| 43           | ASTM F1929-15                          | Standard Test Method for Detecting Seal Leaks in Porous Medical Packaging by Dye Penetration  |
| 44           | ASTM F1980-21                          | Standard Guide for Accelerated Aging of Sterile Barrier Systems and Medical Devices   |
| 45           | ASTM F88 / F88M-23                     | Standard Test Method for Seal Strength of Flexible Barrier Materials  |
| 46           | ASTM D5276 - 19                        | Standard Test Method for Drop Test of Loaded Containers by Free Fall  |
| 47           | MEDDEV 2. 4/1 Rev. 9                   | MEDICAL DEVICES: Guidance document - Classification of medical devices  |
| 48           | MEDDEV 2. 2/3 rev.3                    | 'Use-by' date for medical devices   |
| 49           | MEDDEV 2.7/1 Rev.04                    | Clinical Evaluation: A Guide for Manufacturers and Notified Bodies Under Directives 93/42/EEC and 90/385/EEC  |
|              |  | KM-AS-ORC-rev00-25.08.2023  |

| Document Code : | Effective Date: | Revision No: | Revision Date: | Number of Pages: |
|-----------------|-----------------|--------------|----------------|------------------|
| YT-DC-RK        | 11.09.2012      | 11           | 02.10.2023     | 4 / 6            |



| 50 | MEDDEV 2.12/2 rev2     | Post-Market Clinical Follow-up Studies   |
|----|------------------------|--|
| 51 | MEDDEV 2.12-1 rev 8    | Guidelines on a Medical Devices Vigilance System   |
| 52 | NB-MED/2.5.1/Rec5-rev4 | <u>Technical</u> Documentation   |
| 53 | NB-MED/2.5.1/Rec6-rev4 | Renewal of EC Design-Examination and Type-Examination Certificates   |
| 54 | NB-MED/2.5.2/Rec1-rev4 | Subcontracting - QS related  |
| 55 | NB-MED/2.12/Rec1-rev11 | Post-Marketing Surveillance (PMS) post market/production   |
| 56 | NB-MED/2.13/Rec1-rev3  | CE-Marking of pre-MDD devices  |
| 57 | MDCG 2018-1 Rev. 4     | Guidance on basic UDI-DI and changes to UDI-DI   |
| 58 | MDCG 2018-2            | Future EU medical device nomenclature - Description of requirements  |
| 59 | MDCG 2018-3 Rev.1      | Guidance on UDI for systems and procedure packs  |
| 60 | MDCG 2018-4            | Definitions/descriptions and formats of the UDI core elements for systems or procedure packs   |
| 61 | MDCG 2018-6            | Clarifications of UDI related responsibilities in relation to article 16   |
| 62 | MDCG 2018-7            | Provisional considerations regarding language issues associated with the UDI database  |
| 63 | MDCG 2019-1            | MDCG guiding principles for issuing entities rules on basic UDI-DI   |
| 64 | MDCG 2019-2            | Guidance on application of UDI rules to device-part of products referred to in article $1(8)$ , $1(9)$ and $1(10)$ of Regulation $745/2017$  |
| 65 | MDCG 2019-4            | Timelines for registration of device data elements in EUDAMED  |
| 66 | MDCG 2019-5            | Registration of legacy devices in EUDAMED  |
| 67 | MDCG 2019-7            | Guidance on article 15 of the medical device regulation (MDR) and in vitro diagnostic device regulation (IVDR) on a 'person responsible for regulatory compliance' (PRRC)  |
| 68 | MDCG 2019-9 Rev.1      | Summary of safety and clinical performance   |
| 69 | MDCG 2020-3 Rev.1      | Guidance on significant changes regarding the transitional provision under Article 120 of the MDR with regard to devices covered by certificates according to MDD or AIMDD   |
| 70 | MDCG 2020-5            | Guidance on clinical evaluation – Equivalence  |
| 71 | MDCG 2020-6            | Guidance on sufficient clinical evidence for legacy devices  |
| 72 | MDCG 2020-7            | Guidance on PMCF plan template   |
| 73 | MDCG 2020-8            | Guidance on PMCF evaluation report template  |
| 74 | MDCG 2020-15           | MDCG Position Paper on the use of the EUDAMED actor registration module and of the Single Registration Number (SRN) in the Member States   |
| 75 | MDCG 2021-1 Rev. 1     | Guidance on harmonised administrative practices and alternative technical solutions until EUDAMED is fully functional  |
| 76 | MDCG 2021-5            | Guidance on standardisation for medical devices  |
| 77 | MDCG 2021-10           | The status of Appendixes E-I of IMDRF N48 under the EU regulatory framework for medical devices  |
| 78 | MDCG 2021-12           | FAQ on the European Medical Device Nomenclature (EMDN)   |
| 79 | MDCG 2021-13 Rev.1     | Questions and answers on obligations and related rules for the registration in EUDAMED of actors other than manufacturers, authorised representatives and importers subject to the obligations of Article 31 MDR and Article 28 IVDR  KM-AS-ORC-rev00-25.08.2023 |

| Document Code : | Effective Date: | Revision No: | Revision Date: | Number of Pages: |
|-----------------|-----------------|--------------|----------------|------------------|
| YT-DC-RK        | 11.09.2012      | 11           | 02.10.2023     | 5/6              |



| 80 | MDCG 2021-19 | Guidance note integration of the UDI within an organisation's quality management system  |
|----|--------------|--|
| 81 | MDCG 2021-24 | Guidance on classification of medical devices  |
| 82 | MDCG 2021-25 | Application of MDR requirements to "legacy devices" and to devices placed on the market prior to 26 May 2021 in accordance with Directives 90/385/EEC or 93/42/EEC |
| 83 | MDCG 2022-7  | Q&A on the Unique Device Identification system under Regulation (EU) 2017/745 and Regulation (EU)  |
| 84 | MDCG 2022-21 | Guidance on Periodic Safety Update Report (PSUR) according to Regulation (EU) 2017/745   |

KM-AS-ORC-rev00-25.08.2023

| Document Code : | Effective Date: | Revision No: | Revision Date: | Number of Pages: |
|-----------------|-----------------|--------------|----------------|------------------|
| YT-DC-RK        | 11.09.2012      | 11           | 02.10.2023     | 6/6              |